Design Therapeutics, Inc.

Friedreich’s Ataxia Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | AbbVie, Minoryx Therapeutics, Takeda, Reata Pharma, Design Therapeutics
StreetInsider · 15 Oct 2026
Design Therapeutics (DSGN) Receives a Buy from Leerink Partners
The Globe and Mail · 14 Oct 2026
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Simply Wall Street · 13 Oct 2026
Design Therapeutics rated 'Hold' as key trial r...
Pluang · 04 Oct 2026
Design Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027
Seeking Alpha · 04 Oct 2026
Design Therapeutics a new overweight at Wells Fargo on Friedreich ataxia program
TradingView · 02 Oct 2026

Headlines from the last 30 days, linking to the original publishers. See all market news →

Disclaimer — PositoAI is a research and screening tool for educational and informational purposes. It is not investment advice or a recommendation to buy or sell any security or mutual fund. Scores and rankings are calculated by PositoAI's own method using publicly available data, which may be incomplete, delayed or inaccurate, and past performance does not indicate future results. AI summaries of company news may contain errors. PositoAI is not registered with the SEC, SEBI or any other regulatory authority. Please do your own research or consult a licensed financial advisor before investing.